XENA®

XENA® is a blood test is based on cell-free MicroRNA biomarkers for the accurate and early detection of ovarian cancer.

1 in 78 Women might develop ovarian cancer in their lifetime.

Ovarian cancer is the most deadly gynaecological cancer and early diagnosis is crucial. In a typical ovarian cancer diagnostic pathway, a patient with non-specific but persistent symptoms such as pelvic pains or abdominal bloating will undergo transvaginal ultrasonography to determine presence of adnexal mass and a CA-125 protein marker blood test, to predict ovarian cancer in relation to elevated CA-125 levels.

These tests are not definitive for ovarian cancer as an adnexal mass could either be benign or malignant. Moreover, CA-125 cannot accurately diagnose early stage ovarian cancer in women, leading to false negative results, and can in fact be elevated in non-ovarian cancer conditions, causing false positive outcomes.

  1. ACS, 2021. Ovarian Cancer. American Cancer Society. Available at: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html

Image for reference purpose only

INEX's Solution

XENA® is a blood test is based on cell-free MicroRNA biomarkers for the accurate and early detection of ovarian cancer.

NON-INVASIVE

XENA® only requires whole blood collected from the arm.

PERFORMANCE

Greatly enhanced accuracy over the current CA125 screening test.

INFORMED CLINICAL DECISIONS

Reduces the need for unnecessary invasive biopsies.

INTERESTED?

If you're interested in XENA® and would like to know more or partner with us, let's chat.